<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852303</url>
  </required_header>
  <id_info>
    <org_study_id>B300201733349</org_study_id>
    <nct_id>NCT03852303</nct_id>
  </id_info>
  <brief_title>Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy</brief_title>
  <acronym>OAETREATe</acronym>
  <official_title>OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of
      Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin
      treatment once a year compared to 2 and 3 times a year. All participants also receive
      anti-epileptic drugs according to local guidelines for epilepsy treatment. Participants will
      be followed for 12 months. The primary endpoint is seizure freedom defined as no seizures
      during the last fourth months of the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of
      Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin
      treatment once a year compared to 2 and 3 times a year. All participants also receive
      anti-epileptic drugs according to local guidelines for epilepsy treatment. Participants will
      be followed for 12 months.The primary endpoint is seizure freedom defined as no seizures
      during the last fourth months of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seizure freedom</measure>
    <time_frame>month 9-12</time_frame>
    <description>no seizures</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>ivermectin once a year</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin one dose per year and anti-epileptic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin 2 times a year</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin one dose 2 times a year and anti-epileptic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin 3 times a year</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vermectin one dose 3 times a year and anti-epileptic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin</intervention_name>
    <description>evaluate effect of ivermectin on frequency of seizures</description>
    <arm_group_label>ivermectin 2 times a year</arm_group_label>
    <arm_group_label>ivermectin 3 times a year</arm_group_label>
    <arm_group_label>ivermectin once a year</arm_group_label>
    <other_name>anti-epileptic treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 5 years and above

          -  Signed informed consent form

          -  Normal neurological development until onset of epilepsy

          -  Onset of epilepsy between ages of 5 and 18 years

          -  Presence of microfilaria in skin snip and/or antibodies against Ov16

        Exclusion Criteria:

          -  Ivermectin intake the last 9 months

          -  Pregnancy or breastfeeding

          -  Known or suspected allergy to Ivermectin

          -  Loa Loa microfilariae in blood

          -  Epilepsy with known cause (e.g. severe head trauma, perinatal asphyxia, patients with
             a history of cerebral malaria, meningitis or encephalitis)

          -  Concomitant acute illness or chronic medication use

          -  Chronic alcohol/substance use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Colebunders, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherche en Maladies Tropicales de l'Ituri</name>
      <address>
        <city>Rethy</city>
        <state>Ituri</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Robert Colebunders</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After publication of results</ipd_time_frame>
    <ipd_access_criteria>Approval of the PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

